Please login to the form below

Not currently logged in
Email:
Password:

Evan Lippman joins Aileron Therapeutics

He has experience at EMD Serono, Pfizer and AstraZeneca
Evan Lippman joins Aileron Therapeutics

Aileron Therapeutics has added to its senior team with the appointment of Evan Lippman as its first chief financial and business officer.

The addition comes as the US biopharma prepares to advance its lead oncology candidate ALRN-6924 into clinical trials.

In Lippman Aileron gains the expertise of a man with great experience in life sciences. Most recently Lippman help a senior VP role at EMD Serono heading the strategy for its US neurology franchise.

Highlights of his career include a spell as executive director at AstraZeneca where he led on huge brands such as Crestor (rosuvastatin calcium) and Nexium (esomeprazole) and heading US business development at the same company.

Lippman's other big pahrma experience includes a period at Pfizer as executive director, worldwide business development and strategic planning.

12th January 2015

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics